Drugs / Aminolaevulinic acid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06439433 | May 2021 → Dec 2023 | cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02631863 | Mar 2016 → Nov 2018 | cervical squamous intraepithelial neoplasia, human papilloma virus infection | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02304770 | Jan 2015 → Jan 2017 | cervical intraepithelial neoplasia, human papilloma virus infection | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aminolaevulinic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06439433 ↗ |
| Known as | ALA | “Aminolaevulinic acid (ALA) photodynamic therapy” NCT02304770 ↗ |
| Route | Topical | “Patients will receive 3 topical treatments of aminolaevulinic acid 500mg” NCT02631863 ↗ |